Navigation Links
Epsen Fuller Group Recruits Operations Leader for Global Biotech Firm SOTIO
Date:4/11/2013

NEW YORK, April 11, 2013 /PRNewswire-iReach/ -- SOTIO a.s, a leader in cell therapy treatments for cancer and autoimmune diseases, has added to their senior leadership team with the addition of Heidi M. Hagen as Chief Operating Officer-US and Head of Global Operations Strategy. As the strategic advisor to SOTIO, Epsen Fuller Group completed the successful placement, which encompassed an exhaustive search of the top operational leaders in biotechnology, and specifically cell manufacturing.

(Photo: http://photos.prnewswire.com/prnh/20130411/CG92806)

"This role is very narrowly focused on cutting-edge therapies based on activated dendritic cells that trigger the immune system for the treatment of cancer and autoimmune diseases", explained Thomas Fuller , Managing Partner of Epsen Fuller Group and leader on his project.

Ms. Hagen is an expert in dendritic cell manufacturing and autologous operations as evidenced in her most recent role as SVP, Operations at Dendreon. Heidi's achievements there were numerous, including building three state-of-the-art, and very high-performing manufacturing facilities, on budget and on schedule. Heidi was formerly at Immunex Corporation, acquired by Amgen, where she held leadership positions in supply chain, clinical operations, and business strategy. Holding an MBA, an MS in Bioengineering, and a BS in cell and molecular biology, all from the University of Washington, Heidi is a widely-recognized authority on cell manufacturing.

"Sotio is focused on becoming a leader in the field of modern biotechnology therapies and related science," says Mr. Fuller. "We were looking for an individual with the real drive and passion to lead the way in commercializing the science of cell manufacturing, thereby enabling SOTIO to flourish as an innovative and fast-growth organization and reinforce its commitment to connecting patients and science."

About SOTIO

SOTIO Group is a biotechnology group developing new therapies based on activated dendritic cells, focusing on the treatment of cancer and autoimmune diseases. Its mission is to develop new medical therapies using SOTIO's proprietary cell-based technologies to treat highly unmet medical conditions using SOTIO's immunotherapy platform. World renowned scientists are working at SOTIO's research facilities in Prague using state-of-the art technologies to understand the role of dendritic cells in the therapeutic activation of the body's immune response. SOTIO plans to start a global pivotal Phase 3 clinical trial which will enroll U.S. as well as E.U. patients under the supervision of FDA and EMA. SOTIO, LLC is an affiliate of SOTIO and is responsible for organizing SOTIO Group's activities in the United States.

About Epsen Fuller Group

New York based Epsen Fuller Group, www.epsenfuller.com, is a Top-20 retained executive search and talent management consulting firm with US offices in New York, New Jersey and San Francisco and offices in major markets and business centers throughout the world, providing instant access to a world-class executive talent pool serving the global economy.

Epsen Fuller Group delivers an integrated suite of talent management solutions throughout four business units focused on the acquisition, assessment, and acceleration of talent. EF|IMD conducts senior executive search, TalentKinect executes mid-management recruitment projects, iDestiny offers a variety of leadership assessment, development, and coaching solutions, while EFAdvisory delivers talent assessment and advisory services to enhance governance best practices in corporate Boards and maximize transaction value for Private Equity Groups. The firm specializes in three industry verticals – consumer, life sciences, and the tech|communications|media sectors - placing top talent in blue-chip client organizations worldwide.

Media Contact:

Kate Hassey , Epsen Fuller Group, 2123924842, khassey@epsenfuller.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Epsen Fuller Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Groupe Athena, Inc. Releases 3rd Quarter Financials, Continues Strong Revenue And Earnings Growth
2. Equatorial Guineas [EG] Ministry of Health convenes in Washington, DC with GB Group Global and TNI Biotech (OTCBB:TNIB) to launch major innovative health solutions and improve pharmaceutical quality for its citizens
3. Digital Marketing Groups Growing, Evolving to Respond to Tumultuous Marketing Landscape
4. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
5. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
6. Chimerixs Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantations Annual Meeting
7. Fortune Magazine Profiles ArcView Group, Co-founded by Steve DeAngelo
8. Bio-pharma Internal Communications Groups Evolving for Structure Optimization
9. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
10. Millennium Research Group Sponsors Case Competition at Western University for Second Year
11. Cellular Biomedicine Group Marks the Launch of China Clinical Trial for TC-DC Therapy for Hepatocellular Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):